Company’s 36-month beta value is 5.58.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ERNA is 20.84M, and currently, short sellers hold a 0.61% ratio of that floaft. The average trading volume of ERNA on June 03, 2025 was 230.06K shares.
ERNA) stock’s latest price update
The stock price of Ernexa Therapeutics Inc (NASDAQ: ERNA) has dropped by -21.28 compared to previous close of 0.22. Despite this, the company has seen a fall of -27.87% in its stock price over the last five trading days. globenewswire.com reported 2025-05-28 that New data finds novel cell therapy successfully converts “cold” ovarian tumors into “hot,” demonstrating potential to unlock immune response and improve outcomes New data finds novel cell therapy successfully converts “cold” ovarian tumors into “hot,” demonstrating potential to unlock immune response and improve outcomes
ERNA’s Market Performance
Ernexa Therapeutics Inc (ERNA) has experienced a -27.87% fall in stock performance for the past week, with a -14.86% drop in the past month, and a -39.70% drop in the past quarter. The volatility ratio for the week is 2.60%, and the volatility levels for the past 30 days are at 4.51% for ERNA. The simple moving average for the past 20 days is -21.85% for ERNA’s stock, with a -72.31% simple moving average for the past 200 days.
ERNA Trading at -16.99% from the 50-Day Moving Average
After a stumble in the market that brought ERNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.43% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at ERNA starting from Cherington Charles, who purchase 3,768,397 shares at the price of $0.10 back on Apr 02 ’25. After this action, Cherington Charles now owns 20,401,602 shares of Ernexa Therapeutics Inc, valued at $394,174 using the latest closing price.
Stock Fundamentals for ERNA
Current profitability levels for the company are sitting at:
- -23.58 for the present operating margin
- 0.81 for the gross margin
The net margin for Ernexa Therapeutics Inc stands at -86.16. The total capital return value is set at 2.35. Equity return is now at value -2264.31, with -168.48 for asset returns.
Based on Ernexa Therapeutics Inc (ERNA), the company’s capital structure generated -0.94 points at debt to capital in total, while cash flow to debt ratio is standing at -4.91. The debt to equity ratio resting at -0.48. The interest coverage ratio of the stock is -2.11.
Currently, EBITDA for the company is -36.12 million with net debt to EBITDA at -0.03. When we switch over and look at the enterprise to sales, we see a ratio of 23.02. The receivables turnover for the company is 3.43for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.21.
Conclusion
In a nutshell, Ernexa Therapeutics Inc (ERNA) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
